Myosotis Investments
Utrechtseweg 48, Zeist, Utrecht, 3704 AE, Netherlands
Overview
Myosotis Investments is a company that provides financial and business support to life science enterprises, with a focus on molecular diagnostics and related fields. It works with clinical and diagnostic ventures by investing capital and supporting business development activities. The firm’s activities include reviewing potential investments and helping portfolio companies develop and advance technologies in healthcare and diagnostics.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 2
- Active investors
- 2
Investment portfolio
- PamDx
Led · Series A · Apr 2026
PamDx develops the IOPener® blood-test platform that rapidly measures protein kinases in cancer patients to support immunotherapy decision-making. The company is advancing clinical programs and preparing for commercialization of the IOPener platform. PamDx recently completed a €13 million Series A financing to fund those efforts. The company operates from an office in Den Bosch and employs over 30 people. Leadership includes chairman Jan van der Hoeven and CEO John Groten, and Helena Bond will act as an observer representing EISMEA. The organization recently rebranded from PamChip to PamDx as part of this next growth phase.
- Scinus Group
Led · Equity · Mar 2026
Scinus Group develops the Osilaris platform (formerly the Scinus Cell Expansion system) for scaling up stem cell cultivation using volume-expandable culture bags to enable 3D cultivation at clinical scale. The system is designed for Good Manufacturing Practice (GMP) compliance to help transition therapies from laboratory vials to clinical doses within a single platform. The company emphasizes clinical-scale, volume-expandable 3D growth rather than traditional 2D flask-based methods. Scinus plans to use the recent €3M strategic investment to expand operations and increase R&D efforts. Leadership changes tied to the investment include appointment of Dr. Erik Vossenaar as Executive Director and the addition of CEO Dr. Janeska de Jonge to the Board as a Non-Executive Director. The company was founded by Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, and FrankJan van der Velden.